Immuneering Corp. (IMRX)
4.61
-0.17
(-3.56%)
USD |
NASDAQ |
Sep 09, 14:40
Immuneering Debt to Equity Ratio : 0.0191 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0191 |
| March 31, 2026 | 0.0181 |
| December 31, 2025 | 0.0175 |
| September 30, 2025 | 0.0172 |
| June 30, 2025 | 0.1383 |
| March 31, 2025 | 0.0976 |
| December 31, 2024 | 0.1006 |
| September 30, 2024 | 0.0735 |
| June 30, 2024 | 0.065 |
| March 31, 2024 | 0.0557 |
| December 31, 2023 | 0.0493 |
| September 30, 2023 | 0.0437 |
| Date | Value |
|---|---|
| June 30, 2023 | 0.0404 |
| March 31, 2023 | 0.0485 |
| December 31, 2022 | 0.0441 |
| September 30, 2022 | 0.0398 |
| June 30, 2022 | 0.0022 |
| March 31, 2022 | 0.0019 |
| December 31, 2021 | 0.0344 |
| September 30, 2021 | 0.0036 |
| June 30, 2021 | -2.372 |
| March 31, 2021 | -2.058 |
| December 31, 2020 | -2.612 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Regeneron Pharmaceuticals, Inc. | 0.0854 |
| ACADIA Pharmaceuticals, Inc. | 0.0565 |
| Alnylam Pharmaceuticals, Inc. | 2.206 |
| Anika Therapeutics, Inc. | 0.1839 |
| Savara, Inc. | 0.2117 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 202.06M |
| Total Liabilities (Quarterly) | 11.32M |
| Shareholders Equity (Quarterly) | 190.74M |
| Current Ratio | 19.47 |
| Net Debt Paydown Yield | 0.03% |